Sight Sciences, Inc. (SGHT)

Sight Sciences highlights a new meta-analysis showing OMNI delivers lasting safety, efficacy and economic value in glaucoma treatment.

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the European Journal of Ophthalmology of a systematic review and meta-analysis of the clinical effectiveness, safety, humanistic and economic impact of the OMNI Surgical System (OMNI).

Sight Sciences, Inc. (NASDAQ:SGHT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Paul Badawi - Co-Founder, President, CEO & Director Alison Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Presentation Unknown Analyst Awesome. Thank you so much.

This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data

MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alison Perry Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Matthew W. Link - Chief Commercial Officer Paul Badawi - Co-Founder, President, CEO & Director Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Joanne Karen Wuensch - Citigroup Inc. Exchange Research Kyle Edward Winborne - Piper Sandler & Co., Research Division Thomas M.

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.25 per share a year ago.

MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guidance while reaffirming its adjusted operating expense guidance, both for full year 2025.

Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research

Mean signs and symptoms for participants in Stage 3 of the SAHARA trial remained statistically significantly better than study baseline at all time points measured up to 24 months Mean signs and symptoms for participants in Stage 3 of the SAHARA trial remained statistically significantly better than study baseline at all time points measured up to 24 months

MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2025, after the market close on Thursday, August 7, 2025.

MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum.

Sight Sciences, Inc. (NASDAQ:SGHT ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Hannah Jefferies - Investor Relations Paul Badawi - Co-Founder & CEO Ali Bauerlein - CFO Matt Link - Chief Commercial Officer Conference Call Participants Tom Stephan - Stifel Danielle Antalffy - UBS Joanne Welsh - Citi Frank Takkinen - Lake Street Capital Markets Macauley Kilbane - William Blair David Saxon - Needham & Company Operator Good day, and thank you for standing by. Welcome to the Sight Sciences First Quarter 2025 Earnings Results Conference Call.

While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.